Customer Validation
- •Cancer Res. 2016 Nov 15;76(22):6631-6642.
- •J Autoimmun. 2017 Jun;80:28-38.
- •Brain Behav Immun. 2017 Jan;59:322-332.
- •Basic Res Cardiol. 2017 Jan;112(1):9.
- •Oncotarget. 2017 May 9;8(19):31802-31814.
- •Oncotarget. 2017 May 2;8(18):29996-30007.
- •Oncotarget. 2017 Mar 28;8(13):21044-21053.
- •Cell Physiol Biochem. 2017 Mar 29;41(4):1675-1683.
- •Sci Rep. 2017 Mar 8;7:43834.
- •Sci Rep. 2017 Mar 8;7:43796.
- •Sci Rep. 2016 Aug 4;6:30957.
- •Sci Rep. 2016 Jun 9;6:27866.
- •J Neurochem. 2017 Oct;143(2):225-235.
- •J Neurochem. 2016 May;137(4):576-88.
- •Exp Cell Res. 2015 Feb 15;331(2):320-30.
- •Mol Pain. 2014 Feb 6;10(1):10.
- •Am J Physiol Gastrointest Liver Physiol. 2016 Dec 1;311(6):G1091-G1104.
- •Am J Physiol Gastrointest Liver Physiol. 2014 Feb;306(3):G244-52.
- •Neuroscience. 2017 Sep 30;360:128-138.
- •Food Funct. 2017 May 24;8(5):1905-1914.
- •Vaccine. 2017 Feb 15;35(7):1037-1045.
- •Vaccine. 2015 Apr 15;33(16):1923-33.
- •Life Sci. 2017 Feb 1;170:25-32.
- •Molecules. 2017 Jul 15;22(7). pii: E1187.
- •PLoS One. 2017 Jul 24;12(7):e0181796.
- •PLoS One. 2017 May 24;12(5):e0178147.
- •Oncol Rep. 2017 Jun;37(6):3341-3350.
- •Vet Microbiol. 2017 May;203:158-166.
- •J Sci Food Agric. 2017 Nov;97(14):4727-4736.
- •Photochem Photobiol. 2016 Nov;92(6):816-825.
- •J Biochem. 2017 Oct 18.
- •Cytotechnology. 2017 Apr;69(2):229-244.
- •BMC Musculoskelet Disord. 2014 Jan 15;15(1):18.
- •Mol Med Rep. 2017 Sep;16(3):3111-3116.
- •Oncol Lett. 2016 Aug;12(2):1034-1040.
- •Biosci Biotechnol Biochem. 2016 Jul;80(7):1393-402.
- •Chin Med J (Engl). 2017 Apr 20;130(8):906-913.
- •University of Arizona. 02-Nov-2017.
- •Biochem Biophys Rep. 2017 Sep;11:147-153.
- •Hainan Med J, Aug. 2017, Vol. 28, No. 15.
- •Chinese Journal of Public Health. 2016, 32(11): 1480-1484.
- •Universität Würzburg. 2016.
- •Seitoku University. 2014.
Description |
TAK-242 is a potent TLR4 signaling inhibitor, selectively inhibits the TLR4-mediated production of cytokines and NO. |
---|---|
IC50 & Target |
TLR4[1] |
In Vitro |
In RAW264.7 cells and mouse peritoneal macrophages, TAK-242 suppresses lipopolysaccharide (LPS)-induced production of NO, tumor necrosis factor-α (TNF-α), and interleukin (IL)-6, with IC50 of 1.1 to 11 nM. TAK-242 also suppresses the production of these cytokines from LPS-stimulated human peripheral blood mononuclear cells (PBMCs) at IC50 values from 11 to 33 nM[1]. |
In Vivo |
TAK-242 apparently reduces the serum anti-dsDNA levels in both genotype mice. Alternatively, IFN-γ, TNF-α, and IL-1β production is markedly inhibited by TAK-242, but their concentrations are still greatly higher than those in NS-treated counterparts[2]. TAK-242 pre-stress administration prevents the accumulation of potentially deleterious inflammatory and oxidative/nitrosative mediators in the brain frontal cortex of rats. TAK-242 i.v. administration at the beginning of the stress session completely blocks TLR-4 mRNA and protein upregulation after stress exposure[3]. |
Clinical Trial |
View MoreCollapse
|
References |
|
Preparing Stock Solutions |
Please refer to the solubility information to select the appropriate solvent.
|
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cell Assay
[1] |
TAK-242 is dissolved in N,N-dimethylformamide, and then diluted with appropriate medium before use[1]. RAW264.7 cells are seeded at a density of 3×106 cells/well in six-well culture plate and incubated overnight. After washing with RPMI 1640 medium supplemented with 1% FCS and 10 μg/mL Kanamycin, the cells are stimulated with 5 ng/mL LPS and 1 U/mL IFN-γ in the presence or absence of TAK-242 (1-100 nM) for the indicated time. Culture supernatants are removed, and total RNA is isolated using the total RNA isolation reagent ISOGEN. Total RNA is reverse transcribed into cDNA by using TaqMan reverse transcription reagents. Quantitative real-time PCR analysis of TNF-α and IL-6 is performed on ABI Prism 7700 using predeveloped TaqMan assay reagents and Universal PCR master mix. Quantitation of mRNA is performed using the comparative threshold cycle method. The highest control level attained by the stimulation (without TAK-242) is regarded as 100%, and the levels of control group at other time points and TAK-242-added group are expressed as the percentage of the highest control level[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Animal Administration
[2][3] |
TAK-242 is dissolved in vehicle (saline) (Mice)[2].
Mice[2] |
||||||||||||||||
References |
|
Molecular Weight |
361.82 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula |
C₁₅H₁₇ClFNO₄S |
||||||||||||
CAS No. |
243984-11-4 |
||||||||||||
Storage |
|
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere |
||||||||||||
Solvent & Solubility |
DMSO: ≥ 360 mg/mL TAK-242 is dissolved in a fat emulsion (i.v. injection)[4]. * "<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> |
||||||||||||
References |
|
Purity: 99.95% ee.: 98.00%
COA (97 KB) HNMR (266 KB) RP-HPLC (236 KB) NP-HPLC (236 KB)
Handling Instructions (1252 KB)-
[1]. Ii M, et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling.
[2]. Ni JQ, et al. Role of toll-like receptor 4 on lupus lung injury and atherosclerosis in LPS-challenge ApoE⁻/⁻ mice. Clin Dev Immunol. 2013;2013:476856.
[3]. Gárate I, et al. Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress. J Neuroinflammation. 2014 Jan 11;11:8.
[4]. Wang L, et al. Doxorubicin-Induced Systemic Inflammation Is Driven by Upregulation of Toll-Like Receptor TLR4 and Endotoxin Leakage. Cancer Res. 2016 Nov 15;76(22):6631-6642.
[5]. Shibata A, et al. Toll-like receptor 4 antagonist TAK-242 inhibits autoinflammatory symptoms in DITRA. J Autoimmun. 2017 Jun;80:28-38.
[6]. Janda J, et al. Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin. Photochem Photobiol. 2016 Nov;92(6):816-825.
[7]. RAO Xiao-jiao, et al. Effect of TLR4 on expression of inflammatory cytokine in aortic artery in mice with insulin resistance[J]. Chinese Journal of Public Health, 2016, 32(11): 1480-1484.